Your browser is no longer supported. Please, upgrade your browser.
Settings
SLS [NASD]
SELLAS Life Sciences Group, Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own1.00% Shs Outstand15.08M Perf Week2.41%
Market Cap118.06M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float14.97M Perf Month-11.03%
Income-16.80M PEG- EPS next Q-0.27 Inst Own10.80% Short Float6.28% Perf Quarter-12.85%
Sales1.90M P/S62.14 EPS this Y80.70% Inst Trans4.02% Short Ratio1.40 Perf Half Y224.10%
Book/sh2.69 P/B3.00 EPS next Y8.50% ROA-70.10% Target Price10.00 Perf Year206.84%
Cash/sh2.41 P/C3.34 EPS next 5Y- ROE-141.00% 52W Range1.76 - 19.38 Perf YTD38.90%
Dividend- P/FCF- EPS past 5Y- ROI-60.60% 52W High-58.36% Beta1.68
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low358.52% ATR0.65
Employees7 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)48.37 Volatility6.26% 7.70%
OptionableYes Debt/Eq0.00 EPS Q/Q76.80% Profit Margin- Rel Volume0.43 Prev Close7.83
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume671.50K Price8.07
Recom2.00 SMA201.05% SMA50-7.35% SMA20047.43% Volume286,175 Change3.07%
Nov-01-18Initiated Oppenheimer Outperform
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
Mar-25-21 06:04AM  
Mar-23-21 04:21PM  
Mar-11-21 08:30AM  
Jan-14-21 08:30AM  
Dec-21-20 08:30AM  
Dec-17-20 08:30AM  
Dec-13-20 08:10PM  
Dec-11-20 08:30AM  
Dec-10-20 04:12PM  
Dec-07-20 08:30AM  
Nov-13-20 04:32PM  
Nov-09-20 09:30AM  
Sep-09-20 08:30AM  
Aug-13-20 04:30PM  
Jul-31-20 01:30PM  
Jul-08-20 07:51PM  
Jun-23-20 08:12AM  
Jun-11-20 08:30AM  
Jun-03-20 09:00AM  
May-22-20 08:30AM  
May-18-20 08:30AM  
May-14-20 04:33PM  
May-07-20 08:00AM  
Apr-28-20 08:30AM  
Apr-16-20 08:30AM  
Mar-18-20 08:30AM  
Mar-13-20 08:30AM  
Mar-10-20 12:03PM  
Feb-26-20 08:30AM  
Feb-14-20 08:30AM  
Feb-11-20 08:30AM  
Feb-10-20 08:45AM  
Jan-13-20 08:30AM  
Jan-10-20 07:13AM  
Jan-09-20 09:00AM  
Jan-08-20 08:30AM  
Jan-06-20 08:15AM  
Dec-04-19 08:00AM  
Nov-19-19 01:28PM  
Nov-14-19 04:30PM  
Nov-08-19 08:00AM  
Nov-06-19 09:20AM  
Aug-14-19 04:15PM  
Aug-05-19 08:30AM  
Jul-31-19 08:15AM  
Jun-22-19 10:10AM  
Jun-18-19 04:33PM  
Jun-14-19 08:30AM  
Jun-03-19 08:30AM  
May-17-19 08:03AM  
May-15-19 04:30PM  
Apr-04-19 08:30AM  
Mar-22-19 08:39AM  
Mar-04-19 08:30AM  
Feb-26-19 10:49AM  
08:30AM  
Feb-12-19 08:45AM  
Jan-31-19 08:30AM  
Jan-08-19 08:30AM  
Dec-06-18 08:30AM  
Nov-30-18 08:30AM  
Nov-28-18 08:30AM  
Nov-26-18 08:30AM  
Nov-15-18 07:30AM  
Nov-12-18 07:00AM  
Nov-09-18 10:00AM  
08:55AM  
08:30AM  
Nov-08-18 08:45AM  
Nov-06-18 09:30AM  
Nov-02-18 08:00AM  
Nov-01-18 10:05AM  
Oct-22-18 07:00AM  
Oct-19-18 08:05AM  
Oct-16-18 01:12PM  
Oct-15-18 08:30AM  
Oct-02-18 04:01PM  
Sep-24-18 04:30PM  
Sep-13-18 08:30AM  
Aug-16-18 09:37AM  
Aug-15-18 08:00AM  
Jul-20-18 11:05AM  
08:30AM  
Jul-16-18 11:23AM  
Jul-12-18 08:45AM  
07:20AM  
Jun-26-18 07:46AM  
Jun-07-18 07:35AM  
Jun-04-18 08:45AM  
Jun-01-18 08:45AM  
May-17-18 08:45AM  
May-09-18 04:30PM  
May-02-18 08:45AM  
Apr-20-18 08:45AM  
Apr-16-18 09:00AM  
Apr-05-18 02:43PM  
Apr-02-18 12:18PM  
08:40AM  
Mar-29-18 01:59PM  
Mar-21-18 08:45AM  
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.